ACAD vs. DYN, RYTM, JANX, INDV, PTCT, MLTX, BHC, MRUS, VERA, and MRVI
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), Indivior (INDV), PTC Therapeutics (PTCT), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), Merus (MRUS), Vera Therapeutics (VERA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
Dyne Therapeutics (NASDAQ:DYN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
ACADIA Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals received 862 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 71.43% of users gave Dyne Therapeutics an outperform vote.
Dyne Therapeutics has a net margin of 0.00% compared to Dyne Therapeutics' net margin of -0.21%. Dyne Therapeutics' return on equity of -0.41% beat ACADIA Pharmaceuticals' return on equity.
Dyne Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, ACADIA Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 27.5% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, ACADIA Pharmaceuticals had 26 more articles in the media than Dyne Therapeutics. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 7 mentions for Dyne Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.92 beat Dyne Therapeutics' score of 0.11 indicating that Dyne Therapeutics is being referred to more favorably in the media.
Dyne Therapeutics presently has a consensus target price of $37.75, suggesting a potential upside of 36.38%. ACADIA Pharmaceuticals has a consensus target price of $28.94, suggesting a potential upside of 95.66%. Given Dyne Therapeutics' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Dyne Therapeutics.
Summary
ACADIA Pharmaceuticals beats Dyne Therapeutics on 12 of the 18 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
